MetaVia is trading 5.4% higher at $1.56 in pre-market, with no clear company-specific catalyst identified for the October 7 move. - The price compares with the October 6 close of $1.48. - The latest company announcement located was September 9, about preclinical tissue-distribution findings for its DA-1726 candidate. - Major U.S. indices were lower before the open, a backdrop that does not clearly explain MetaVia’s rise.